{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:54:05Z","timestamp":1790776445830,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Many patients with inflammatory bowel disease (IBD) show an inadequate response or experience a loss of response to advanced therapies. Guidelines recommend dose optimization and switching among therapies until an optimal treatment response is attained. With several advanced treatments available, we aimed to evaluate the persistence of different therapeutic sequences in IBD.<\/jats:p>\n               <jats:p>The RECORDED study was a retrospective cohort study of Canadians with moderate-to-severely active ulcerative colitis (UC) or Crohn\u2019s disease (CD) who had been exposed to more than 1 advanced therapy between May 2015 and April 2021 for UC, and May 2016 and April 2021 for CD. The primary endpoint was time to permanent discontinuation of the first advanced treatment.<\/jats:p>\n               <jats:p>Overall, 330 patients had CD and 344 had UC. The most common first-line treatments for CD and UC were adalimumab and infliximab, respectively. The median (95% CI) time to permanent discontinuation of first-line treatment was 12.3 (10.9, 13.6) months in patients with CD and 9.2 (8.2, 10.8) months for those with UC. The most common reason for treatment change across both diseases was lack of efficacy. First-line advanced treatments were optimized in 191 (58.1%) CD patients and 202 (59.1%) UC patients prior to permanent discontinuation. Second-line therapy was typically from a different class compared with the first-line treatment choice.<\/jats:p>\n               <jats:p>The RECORDED study provides insights into the real-world sequencing and optimization patterns of advanced treatments in patients with moderate-to-severe IBD in Canada. Lack of efficacy was the most cited reason for switching to a different therapy.<\/jats:p>","DOI":"10.1093\/jcag\/gwae040","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T20:58:32Z","timestamp":1730235512000},"page":"21-30","source":"Crossref","is-referenced-by-count":4,"title":["Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9076","authenticated-orcid":false,"given":"Laura","family":"Targownik","sequence":"first","affiliation":[{"name":"Department of Gastroenterology & Hepatology, University of Toronto, Mount Sinai Hospital , 600 University avenue, Toronto, ON M5G 1X5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal General Hospital , Montreal, Quebec H3G 1A4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of British Columbia, Kelowna General Hospital , Kelowna, British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Siffledeen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta , Edmonton, Alberta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary , Calgary, Alberta"},{"name":"Division of Gastroenterology & Hepatology, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , Calgary, Alberta T2N 4N1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McHugh","sequence":"additional","affiliation":[{"name":"AbbVie Corp. , Saint-Laurent, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Charbonneau","sequence":"additional","affiliation":[{"name":"AbbVie Corp. , Saint-Laurent, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Charles","family":"Rioux","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Montr\u00e9al, H\u00f4pital Maisonneuve-Rosemont , Montreal, Quebec"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"3","key":"2025020307452297700_CIT0001","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/jcag\/gwz019","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for the management of luminal Crohn\u2019s disease","volume":"2","author":"Panaccione","year":"2019","journal-title":"J Can Assoc Gastroenterol."},{"issue":"5","key":"2025020307452297700_CIT0002","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"5","key":"2025020307452297700_CIT0003","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology."},{"issue":"1","key":"2025020307452297700_CIT0004","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology."},{"issue":"9","key":"2025020307452297700_CIT0005","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut."},{"issue":"5","key":"2025020307452297700_CIT0006","first-page":"317","article-title":"Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results","volume":"9","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"23","key":"2025020307452297700_CIT0007","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med."},{"issue":"11","key":"2025020307452297700_CIT0008","first-page":"CD012623","article-title":"Infliximab for medical induction of remission in Crohn\u2019s disease","volume":"11","author":"Gordon","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2025020307452297700_CIT0009","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"issue":"8","key":"2025020307452297700_CIT0010","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"issue":"20","key":"2025020307452297700_CIT0011","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"issue":"13","key":"2025020307452297700_CIT0012","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"issue":"2","key":"2025020307452297700_CIT0013","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review","volume":"14","author":"Colombel","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"10114","key":"2025020307452297700_CIT0014","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/s0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2018","journal-title":"Lancet."},{"issue":"5","key":"2025020307452297700_CIT0015","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"1","key":"2025020307452297700_CIT0016","doi-asserted-by":"publisher","first-page":"e000476","DOI":"10.1136\/bmjgast-2020-000476","article-title":"Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience","volume":"7","author":"Hoque","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"issue":"5","key":"2025020307452297700_CIT0017","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ibd\/izy322","article-title":"Treatment persistence of infliximab versus Adalimumab in ulcerative colitis: a 16-year single-center experience","volume":"25","author":"Pouillon","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2025020307452297700_CIT0018","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/03007995.2022.2071041","article-title":"Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases","volume":"38","author":"Sah","year":"2022","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"2025020307452297700_CIT0019","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.dld.2021.08.020","article-title":"Effectiveness of adalimumab for ulcerative colitis: a multicentre, retrospective study of clinical practice in Italy","volume":"54","author":"Vitello","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"2","key":"2025020307452297700_CIT0020","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/jgh3.12670","article-title":"Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn\u2019s disease: real-world data analysis","volume":"6","author":"Banon","year":"2022","journal-title":"JGH Open"},{"issue":"3","key":"2025020307452297700_CIT0021","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn\u2019s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study","volume":"54","author":"Ko","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2025020307452297700_CIT0022","doi-asserted-by":"publisher","first-page":"otab076","DOI":"10.1093\/crocol\/otab076","article-title":"Persistence, dosing, and other treatment patterns among Crohn\u2019s disease patients initiating biologics in United States","volume":"3","author":"Teeple","year":"2021","journal-title":"Crohns Colitis 360."},{"issue":"4","key":"2025020307452297700_CIT0023","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MOG.0000000000000536","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug","volume":"35","author":"Papamichael","year":"2019","journal-title":"Curr Opin Gastroenterol."},{"key":"2025020307452297700_CIT0024","volume-title":"Product Monograph","year":"2022"},{"key":"2025020307452297700_CIT0025","volume-title":"Product Monograph","year":"2022"},{"issue":"5","key":"2025020307452297700_CIT0026","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cgh.2023.10.029","article-title":"ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse","volume":"22","author":"Jairath","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2025020307452297700_CIT0027","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/apt.17751","article-title":"Clinical trial: clinical and endoscopic outcomes with ustekinumab in patients with Crohn\u2019s disease: Results from the long-term extension period of STARDUST","volume":"59","author":"Peyrin-Biroulet","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"issue":"1S Suppl 1","key":"2025020307452297700_CIT0028","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1097\/MEG.0000000000002256","article-title":"Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn\u2019s disease","volume":"33","author":"Ten Bokkel Huinink","year":"2021","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2025020307452297700_CIT0029","volume-title":"Product Monograph","year":"2021"},{"key":"2025020307452297700_CIT0030","volume-title":"Product Monograph","year":"2022"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/8\/1\/21\/60210019\/gwae040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/8\/1\/21\/60210019\/gwae040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T07:45:45Z","timestamp":1738568745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/8\/1\/21\/7849536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwae040","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,10,29]]}}}